Top

Population Health Metrics

Published in:

Open Access 01-12-2017 | Research

Incidence and survival of end-stage kidney disease due to polycystic kidney disease in Australia and New Zealand (1963–2014)

Authors: Mangalee R. Fernando, Hannah Dent, Stephen P. McDonald, Gopala K. Rangan

Published in: Population Health Metrics | Issue 1/2017

Abstract

Background

The aim of this study was to determine whether the incidence and survival of patients with end-stage kidney disease (ESKD) due to polycystic kidney disease (PKD) has changed in Australia and New Zealand.

Methods

Data for all PKD patients who developed ESKD and commenced renal replacement therapy (RRT) was assessed using the Australia and New Zealand Dialysis and Transplant Registry from 1963 to 2014.

Results

A total 4678 patients with ESKD due to PKD received RRT during the study period. The incidence rate of ESKD (per million population per year) due to PKD rose by 3.2-fold (1970–2010), but the percentage increase between each decade decreased (54.4, 43.8, 25.6 and 6.57%). The median age of onset of new patients developing ESKD has been stable since 1990. Haemodialysis was the most common initial mode of RRT (between 62 and 76% of patients) whereas 24–29% received peritoneal dialysis. The 5-year survival rate of PKD patients on RRT (censored for transplantation and adjusted for age) improved from 26 to 84%, with the percentage increase between each successive time period being 123, 7, 21, 19 and 7.4%. The percentage of deaths on RRT due to cerebrovascular disease declined from 15 to 6%.

Conclusions

The incidence and age of onset of ESKD due to PKD has remained unchanged in the modern era though patient survival on RRT has continued to improve. These data suggest that the development and implementation of disease-specific treatments prior to RRT is needed to effectively diminish the incidence of ESKD due to PKD.

Iglesias CG, Torres VE, Offord KP, Holley KE, Beard CM, Kurland LT. Epidemiology of adult polycystic kidney disease, Olmsted County, Minnesota: 1935–1980. Am J Kidney Dis. 1983;2:630–9.CrossRefPubMed

Kaariainen H. Polycystic kidney disease in children: a genetic and epidemiological study of 82 Finnish patients. J Med Genet. 1987;24:474–81.CrossRefPubMedPubMedCentral

Abbott KC, Agodoa LY. Polycystic kidney disease at end-stage renal disease in the United States: patient characteristics and survival. Clin Nephrol. 2002;57:208–14.CrossRefPubMed

Grantham JJ, Mulamalla S, Swenson-Fields KI. Why kidneys fail in autosomal dominant polycystic kidney disease. Nat Rev Nephrol. 2011;7:556–66.CrossRefPubMed

Corradi V, Gastaldon F, Virzi GM, de Cal M, Soni S, Chionh C, Cruz DN, Clementi M, Ronco C. Clinical pattern of adult polycystic kidney disease in a northeastern region of Italy. Clin Nephrol. 2009;72:259–67.CrossRefPubMed

Rangan GK, Lopez-Vargas P, Nankivell BJ, Tchan M, Tong A, Tunnicliffe DJ, Savige J. Autosomal dominant polycystic kidney disease: a path forward. Semin Nephrol. 2015;35:524–37.CrossRefPubMed

Harris PC, Rossetti S. Molecular diagnostics for autosomal dominant polycystic kidney disease. Nat Rev Nephrol. 2010;6:197–206.CrossRefPubMedPubMedCentral

Perrone RD, Ruthazer R, Terrin NC. Survival after end-stage renal disease in autosomal dominant polycystic kidney disease: contribution of extrarenal complications to mortality. Am J Kidney Dis. 2001;38:777–84.CrossRefPubMed

Alam A, Perrone RD. Management of ESRD in patients with autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis. 2010;17:164–72.CrossRefPubMed

10.

Lee PW, Chien CC, Yang WC, Wang JJ, Lin CC. Epidemiology and mortality in dialysis patients with and without polycystic kidney disease: a national study in Taiwan. J Nephrol. 2012;26:755–62.CrossRefPubMed

11.

Orskov B, Romming Sorensen V, Feldt-Rasmussen B, Strandgaard S. Improved prognosis in patients with autosomal dominant polycystic kidney disease in Denmark. Clin J Am Soc Nephrol. 2010;5:2034–9.CrossRefPubMedPubMedCentral

12.

Spithoven E, Kramer A, Wanner C, Jager KJ, Gansevoort RT. Incidence of renal replacement therapy in Europe. J Am Soc Nephrol. 2013;24:691A.CrossRef

13.

Helal I, McFann K, Reed B, Yan XD, Schrier RW. Changing referral characteristics of patients with autosomal dominant polycystic kidney disease. Am J Med. 2013;126:832 e837–11.CrossRef

14.

Cadnapaphornchai MA, George DM, McFann K, Wang W, Gitomer B, Strain JD, Schrier RW. Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2014;9:889–96.CrossRefPubMedPubMedCentral

15.

Schrier RW, Abebe KZ, Perrone RD, Torres VE, Braun WE, Steinman TI, Winklhofer FT, Brosnahan G, Czarnecki PG, Hogan MC, Miskulin DC, Rahbari-Oskoui FF, Grantham JJ, Harris PC, Flessner MF, Bae KT, Moore CG, Chapman AB, Investigators H-PT. Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med. 2014;371:2255–66.CrossRefPubMedPubMedCentral

16.

Jin DC. Major changes and improvements of dialysis therapy in Korea: review of end-stage renal disease registry. Korean J Intern Med. 2015;30:17–22.CrossRefPubMed

17.

McDonald SP, Russ GR. Australian registries-ANZDATA and ANZOD. Transplant Rev. 2013;27:46–9.CrossRef

18.

Davies F, Coles GA, Harper PS, Williams AJ, Evans C, Cochlin D. Polycystic kidney disease re-evaluated: a population-based study. Q J Med. 1991;79:477–85.PubMed

19.

de Almeida E, Sousa A, Pires C, Aniceto J, Barros S, Prata MM. Prevalence of autosomal-dominant polycystic kidney disease in Alentejo, Portugal. Kidney Int. 2001;59:2374.CrossRefPubMed

20.

Higashihara E, Nutahara K, Kojima M, Tamakoshi A, Yoshiyuki O, Sakai H, Kurokawa K. Prevalence and renal prognosis of diagnosed autosomal dominant polycystic kidney disease in Japan. Nephron. 1998;80:421–7.CrossRefPubMed

21.

Neumann HP, Jilg C, Bacher J, Nabulsi Z, Malinoc A, Hummel B, Hoffmann MM, Ortiz-Bruechle N, Glasker S, Pisarski P, Neeff H, Kramer-Guth A, Cybulla M, Hornberger M, Wilpert J, Funk L, Baumert J, Paatz D, Baumann D, Lahl M, Felten H, Hausberg M, Zerres K, Eng C, Else Kroener Fresenius AR. Epidemiology of autosomal-dominant polycystic kidney disease: an in-depth clinical study for south-western Germany. Nephrol Dial Transplant. 2013;28:1472–87.CrossRefPubMed

22.

Simon P, Le Goff JY, Ang KS, Charasse C, Le Cacheux P, Cam G. Epidemiologic data, clinical and prognostic features of autosomal dominant polycystic kidney disease in a French region. Nephrologie. 1996;17:123–30.PubMed

23.

Yersin C, Bovet P, Wauters JP, Schorderet DF, Pescia G, Paccaud F. Frequency and impact of autosomal dominant polycystic kidney disease in the Seychelles (Indian Ocean). Nephrol Dial Transplant. 1997;12:2069–74.CrossRefPubMed

24.

McDonald SP, Russ GR, Kerr PG, Collins JF. Australia, New Zealand D, Transplant R: ESRD in Australia and New Zealand at the end of the millennium: a report from the ANZDATA registry. Am J Kidney Dis. 2002;40:1122–31.CrossRefPubMed

25.

Florijn KW, Noteboom WM, van Saase JL, Chang PC, Breuning MH, Vandenbroucke JP. A century of mortality in five large families with polycystic kidney disease. Am J Kidney Dis. 1995;25:370–4.CrossRefPubMed

26.

Epstein BJ, Leonard PT, Shah NK. The evolving landscape of RAAS inhibition: from ACE inhibitors to ARBs, to DRIs and beyond. Expert Rev Cardiovasc Ther. 2012;10:713–25.CrossRefPubMed

27.

Kalra PA, Kumwenda M, MacDowall P, Roland MO. Questionnaire study and audit of use of angiotensin converting enzyme inhibitor and monitoring in general practice: the need for guidelines to prevent renal failure. BMJ. 1999;318:234–7.CrossRefPubMedPubMedCentral

28.

Schwenger V, Ritz E. Audit of antihypertensive treatment in patients with renal failure. Nephrol Dial Transplant. 1998;13:3091–5.CrossRefPubMed

29.

Pilotto LS, Ball PA, Smithard JM, Kennedy DR. Electronic records suggest suboptimal management of chronic kidney disease in general practice. Aust J Rural Health. 2012;20:195–9.CrossRefPubMed

30.

Orskov B, Christensen KB, Feldt-Rasmussen B, Strandgaard S. Low birth weight is associated with earlier onset of end-stage renal disease in Danish patients with autosomal dominant polycystic kidney disease. Kidney Int. 2012;81:919–24.CrossRefPubMed

31.

Johnson D, Usherwood T. Automated reporting of GFR--coming soon to a laboratory near you! Aust Fam Physician. 2005;34:925–31.PubMed

32.

Thong KM, Ong AC. The natural history of autosomal dominant polycystic kidney disease: 30-year experience from a single centre. QJM. 2013;106:639–46.CrossRefPubMed

33.

Blanchette CM, Liang C, Lubeck DP, Newsome B, Rossetti S, Gu X, Gutierrez B, Lin ND. Progression of autosomal dominant kidney disease: measurement of the stage transitions of chronic kidney disease. Drugs Context. 2015;4:212275.PubMedPubMedCentral

34.

Boertien WE, Meijer E, Li J, Bost JE, Struck J, Flessner MF, Gansevoort RT, Torres VE. Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease C: Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort. Am J Kidney Dis. 2013;61:420–9.CrossRefPubMed

35.

Graham AN, Neale TJ, Hatfield PJ, Morrison RB, Meech PR, Jacobson A, Faircloth C. Endstage renal failure due to polycystic kidney disease managed by continuous ambulatory peritoneal dialysis. N Z Med J. 1986;99:491–3.PubMed

36.

Modi KB, Grant AC, Garret A, Rodger RS. Indirect inguinal hernia in CAPD patients with polycystic kidney disease. Adv Perit Dial. 1989;5:84–6.PubMed

37.

Fletcher S, Turney JH, Brownjohn AM. Increased incidence of hydrothorax complicating peritoneal dialysis in patients with adult polycystic kidney disease. Nephrol Dial Transplant. 1994;9:832–3.PubMed

38.

Kumar S, Fan SL, Raftery MJ, Yaqoob MM. Long term outcome of patients with autosomal dominant polycystic kidney diseases receiving peritoneal dialysis. Kidney Int. 2008;74:946–51.CrossRefPubMed

39.

Lobbedez T, Touam M, Evans D, Ryckelynck JP, Knebelman B, Verger C. Peritoneal dialysis in polycystic kidney disease patients. Report from the French peritoneal dialysis registry (RDPLF). Nephrol Dial Transplant. 2011;26:2332–9.CrossRefPubMed

40.

Portoles JM, Tato AM, Lopez-Sanchez P. Peritoneal dialysis for patients with polycystic kidney disease in Spain. Am J Kidney Dis. 2011;58:493–4.CrossRefPubMed

41.

Li L, Szeto CC, Kwan BC, Chow KM, Leung CB, Kam-Tao Li P. Peritoneal dialysis as the first-line renal replacement therapy in patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis. 2011;57:903–7.CrossRefPubMed

42.

Courivaud C, Roubiou C, Delabrousse E, Bresson-Vautrin C, Chalopin JM, Ducloux D. Polycystic kidney size and outcomes on peritoneal dialysis compared with haemodialysis. Clin Kidney J. 2014;7:138–43.CrossRefPubMedPubMedCentral

43.

Allepuz A, Martinez O, Tebe C, Nardi J, Portabella F, Espallargues M, Catalan Arthroplasty R. Joint registries as continuous surveillance systems: the experience of the Catalan Arthroplasty Register (RACat). J Arthroplasty. 2014;29:484–90.CrossRefPubMed

44.

Neumann HP, Malinoc A, Bacher J, Nabulsi Z, Ivanovas V, Bruechle NO, Mader I, Hoffmann MM, Riegler P, Kraemer-Guth A, Burchardi C, Schaeffner E, Martin RS, Azurmendi PJ, Zerres K, Jilg C, Eng C, Glasker S. Characteristics of intracranial aneurysms in the else kroner-fresenius registry of autosomal dominant polycystic kidney disease. Cerebrovasc Dis Extra. 2012;2:71–9.CrossRefPubMedPubMedCentral

45.

Orskov B, Sorensen VR, Feldt-Rasmussen B, Strandgaard S. Changes in causes of death and risk of cancer in Danish patients with autosomal dominant polycystic kidney disease and end-stage renal disease. Nephrol Dial Transplant. 2012;27:1607–13.CrossRefPubMed

46.

Patil A, Sweeney Jr WE, Avner ED, Pan C. Childhood polycystic kidney disease. In: LI X, editor. Polycystic kidney disease. Brisbane: AU; 2015.

47.

Rangan GK, Lee VW, Alexander SI, Patel C, Tunnicliffe DJ, Vladica P. KHA-CARI autosomal dominant polycystic kidney disease guideline: screening for polycystic kidney disease. Semin Nephrol. 2015;35:557–564 e556.CrossRefPubMed

48.

Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367(25):2407–18.CrossRefPubMedPubMedCentral

49.

Grantham JJ. Rationale for early treatment of polycystic kidney disease. Pediatr Nephrol. 2015;30:1053–62.CrossRefPubMed

Title: Incidence and survival of end-stage kidney disease due to polycystic kidney disease in Australia and New Zealand (1963–2014)
Authors: Mangalee R. Fernando
Hannah Dent
Stephen P. McDonald
Gopala K. Rangan
Publication date: 01-12-2017
Publisher: BioMed Central
Published in: Population Health Metrics / Issue 1/2017
Electronic ISSN: 1478-7954
DOI: https://doi.org/10.1186/s12963-017-0123-7

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Incidence and survival of end-stage kidney disease due to polycystic kidney disease in Australia and New Zealand (1963–2014)

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2017

The effects of economic development and built environment on diabetes in China

Evolution of the “fourth stage” of epidemiologic transition in people aged 80 years and over: population-based cohort study using electronic health records

Comparing trends in mortality from cardiovascular disease and cancer in the United Kingdom, 1983–2013: joinpoint regression analysis

Change in life expectancy with type 2 diabetes: a study using claims data from lower Saxony, Germany

Multivariable regression analysis of list experiment data on abortion: results from a large, randomly-selected population based study in Liberia

National disability-adjusted life years (DALYs) for 257 diseases and injuries in Ethiopia, 1990–2015: findings from the global burden of disease study 2015